Page last updated: 2024-12-06
4-nitroperbenzoic acid
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 70342 |
| SCHEMBL ID | 248294 |
| MeSH ID | M0068422 |
Synonyms (26)
| Synonym |
|---|
| 4-nitro-benzenecarboperoxoic acid |
| peroxybenzoic acid, p-nitro- |
| 4-nitroperbenzoic acid |
| p-nitroperoxybenzoic acid |
| p-nitroperbenzoic acid |
| wln: wnr dvoq |
| nsc68056 |
| benzenecarboperoxoic acid, 4-nitro- |
| 943-39-5 |
| nsc-68056 |
| 4-nitroperoxybenzoic acid |
| caswell no. 602a |
| epa pesticide chemical code 597100 |
| nsc 68056 |
| einecs 213-401-2 |
| brn 1075774 |
| 4-nitrobenzenecarboperoxoic acid |
| unii-z949x35pl0 |
| z949x35pl0 , |
| 4-09-00-01189 (beilstein handbook reference) |
| nitroperoxybenzoic acid, 4- |
| nitroperoxybenzoic acid, p- |
| SCHEMBL248294 |
| ZJAFQAPHWPSKRZ-UHFFFAOYSA-N |
| DTXSID4041523 |
| Q27295168 |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " This contributes to the lower oral clearance (CL/F), apparent volume of distribution (Vss/F) and longer half-life (t(1/2)) that TPM has in blood compared to the CL/F, Vss/F and t(1/2), estimated from plasma data." | ( Plasma and whole blood pharmacokinetics of topiramate: the role of carbonic anhydrase. Bialer, M; Doose, DR; Shank, RP; Streeter, AJ, 2005) | 0.33 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.54
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.54) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (16.67%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (83.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||